US Stem Cell Inc (USRM)

[Xpecht]

The price jumped back in March 2017 because of a long shot attempt at FDA RMAT endorsement which didn’t have a clear path. As people learned RMAT was not going to happen overnight the stock price declined. RMAT would have helped but this is going to get public approval and demand and therefore RMAT isn’t necessary. Just was a shortcut. But it provides a window into what the share price will do once this continues its path to mainstream medicine. If you believe stem cells have a future then this is a good play IMO.